New Zealand - English - Medsafe (Medicines Safety Authority)

chiesi new zealand limited t/a emerge health - cannabidiol 100 mg/ml;  ;  ;   - oral solution - 100 mg/ml - active: cannabidiol 100 mg/ml       excipient: ethanol sesame oil strawberry flavour 501094 a sucralose - epidyolex is indicated for use as adjunctive therapy of seizures associated with lennox-gastaut syndrome (lgs) or dravet syndrome (ds) for patients 2 years of age and older.

New Zealand - English - Medsafe (Medicines Safety Authority)

chiesi new zealand limited t/a emerge health - stiripentol 250mg;   - capsule - 250 mg - active: stiripentol 250mg   excipient: erythrosine   gelatin   indigo carmine   ink black 10a2 magnesium stearate povidone sodium starch glycolate titanium dioxide   - indicated for adjunctive treatment of generalised tonic-clonic and clonic seizures associated with severe myoclonic epilepsy in infancy (smei, also known as dravet syndrome) in patients whose seizures are not adequately controlled with a benzodiazepine (usually clobazam) and valproate.

New Zealand - English - Medsafe (Medicines Safety Authority)

chiesi new zealand limited t/a emerge health - stiripentol 500mg;   - capsule - 500 mg - active: stiripentol 500mg   excipient: gelatin   ink black 10a2 magnesium stearate povidone sodium starch glycolate titanium dioxide   - indicated for adjunctive treatment of generalised tonic-clonic and clonic seizures associated with severe myoclonic epilepsy in infancy (smei, also known as dravet syndrome) in patients whose seizures are not adequately controlled with a benzodiazepine (usually clobazam) and valproate.

New Zealand - English - Medsafe (Medicines Safety Authority)

chiesi new zealand limited t/a emerge health - stiripentol 250mg;   - powder for oral suspension - 250 mg - active: stiripentol 250mg   excipient: aspartame carmellose sodium erythrosine hyetellose spray-dried glucose liquid povidone sodium starch glycolate titanium dioxide tutti frutti flavour 25h245 - indicated for adjunctive treatment of generalised tonic-clonic and clonic seizures associated with severe myoclonic epilepsy in infancy (smei, also known as dravet syndrome) in patients whose seizures are not adequately controlled with a benzodiazepine (usually clobazam) and valproate.

New Zealand - English - Medsafe (Medicines Safety Authority)

chiesi new zealand limited t/a emerge health - stiripentol 500mg;   - powder for oral suspension - 500 mg - active: stiripentol 500mg   excipient: aspartame carmellose sodium erythrosine hyetellose spray-dried glucose liquid povidone sodium starch glycolate titanium dioxide tutti frutti flavour 25h245 - indicated for adjunctive treatment of generalised tonic-clonic and clonic seizures associated with severe myoclonic epilepsy in infancy (smei, also known as dravet syndrome) in patients whose seizures are not adequately controlled with a benzodiazepine (usually clobazam) and valproate.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chiesi ltd - formoterol fumarate dihydrate - pressurised inhalation - 12microgram/1dose

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chiesi ltd - formoterol fumarate dihydrate; beclometasone dipropionate - pressurised inhalation - 6microgram ; 200microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chiesi ltd - formoterol fumarate dihydrate; beclometasone dipropionate - pressurised inhalation - 6microgram/1dose ; 100microgram/1dose

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chiesi ltd - tobramycin - nebuliser liquid - 75mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chiesi ltd - poractant alfa - suspension for endotracheopulmonary instillation - 80mg/1ml